Evidence supporting the use of: Magnolol
For the health condition: Parkinson's Disease

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Magnolol, a bioactive compound extracted from the bark of Magnolia officinalis, has attracted interest for its neuroprotective properties, particularly in the context of neurodegenerative diseases like Parkinson's Disease (PD). Scientific studies, primarily preclinical (in vitro and animal models), have demonstrated that magnolol exhibits antioxidant, anti-inflammatory, and antiapoptotic effects, which are believed to be beneficial in mitigating the neuronal damage characteristic of PD. For example, research has shown that magnolol can attenuate dopaminergic neuronal loss by inhibiting microglial activation and reducing oxidative stress in toxin-induced models of PD (Chen et al., 2015; Zhu et al., 2014). Furthermore, magnolol has been reported to modulate signaling pathways associated with cell survival and mitochondrial function, which may offer further neuroprotection.

However, despite these promising preclinical findings, there is currently a lack of robust clinical evidence in humans supporting the efficacy of magnolol as a treatment for Parkinson's Disease. No large-scale randomized controlled trials have been conducted to establish its safety and effectiveness in PD patients. Thus, while the scientific rationale is supported by animal and cellular data, translation to clinical practice is premature. The evidence rating is 2, reflecting promising but early-stage scientific validation.

More about Magnolol
More about Parkinson's Disease

Products containing Magnolol

We currently have no products on Vitabase that contain this ingredient.